Binder Groesswang, working alongside lead counsel Kirkland & Ellis, has advised GTCR and Corza Health on its acquisition of TachoSil Surgical Patch from Takeda, the subsequent merger with Surgical Specialties, and the resulting founding of Corza Medical. Takeda was advised by Linklaters.
Takeda announced the divestment on September 16, 2020, and announced that it will receive "EUR 350 million in cash upon closing of the transaction, which is subject to customary legal and regulatory closing conditions."
“This announcement continues Takeda’s strong momentum toward optimizing our portfolio for growth by delivering highly-innovative medicines and transformative care in our chosen business areas, as well as meeting our leverage targets," commented Costa Saroukos, Chief Financial Officer of Takeda. "As we continue to streamline and simplify our portfolio, Takeda is confident that we have found the right partner in Corza Health as the next home for TachoSil. Corza Health’s expertise in healthcare, commitment to patients, customers, and employees, and resources in partnership with GTCR make it well-positioned to ensure continued patient access to TachoSil and to invest in the product over the long term for their benefit.”
Binder Groesswang's team advising on Austrian matters consisted of Partners Thomas Schirmer, Gottfried Gassner, and Johannes Barbist, Lawyers Wolfgang Guggenberger and Regina Kroell, and Associates Pia-Alena Havel and Felix Fuith.
Kirkland & Ellis's London-based team was led by Partners Jacob Traff, Christopher Thomas, Michael Weed, Sanford Perl, and David Higgins
Linklaters' London-based team was led by Partners Aisling Zarraga and James Inglis and included Partners Marly Didizian, Jonas Koponen, and Thomas McGrath, and Managing Associate Rich Jones.
